RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy
Cancer Immunology, Immunotherapy · 17.03.2026 · 75 (4)
DOI: 10.1007/s00262-026-04356-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 17.03.2026. Verfasst von Lin Mao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. Hauptthemen laut MEDLINE: Dendritic Cells, Receptor-Interacting Protein Serine-Threonine Kinases, Cancer Vaccines, Immunotherapy. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Key Research and Development Program of China, the Global Common Challenges Project of the Chinese Academy of Sciences, Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
- School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
- ANDA Biology Medicine Development (BeiJing) Co., Ltd, Beijing, China.
- Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. hbzhang@sinh.ac.cn.
- Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. ldhu2013@163.com.
- ANDA Biology Medicine Development (BeiJing) Co., Ltd, Beijing, China. ldhu2013@163.com.
Förderung
- the National Key Research and Development Program of China
- the Global Common Challenges Project of the Chinese Academy of Sciences
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
Zitieren
APA
Mao, L., Ou, Y., Zhang, Y., Wang, M., Dong, G., Khanniche, A., Wang, H., Wu, Z., Zhang, H., Hu, L., & Kong, X. (2026). RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy. Cancer Immunology, Immunotherapy, 75(4). https://doi.org/10.1007/s00262-026-04356-5
Vancouver
Mao L, Ou Y, Zhang Y, Wang M, Dong G, Khanniche A, et al. RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy. Cancer Immunology, Immunotherapy. 2026;75(4). doi:10.1007/s00262-026-04356-5
BibTeX
@article{Mao2026,
author = {Mao, Lin and Ou, Yangjing and Zhang, Yuchao and Wang, Minghui and Dong, Guoqing and Khanniche, Asma and Wang, Hailong and Wu, Zhenchuan and Zhang, Haibing and Hu, Landian and Kong, Xiangyin},
title = {RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
volume = {75},
number = {4},
doi = {10.1007/s00262-026-04356-5}
}
EUVIMED